Clinic Follow-Up (Egypt)6 min read

Fatty Liver Follow-Up Program for Private Clinics in Egypt: From Ultrasound Finding to Risk Check

By

A fatty liver follow-up program for a private clinic in Egypt is a routine that turns an ultrasound finding into a recorded risk check: metabolic conditions, a non-invasive fibrosis score such as FIB-4, and a recall date. Egyptian practice guidance cites a metabolic-associated fatty liver disease prevalence of about 47.5%, with 56.7% showing fibrosis in one cited study.

Key takeaways

  • Egyptian practice guidance on metabolic-associated fatty liver disease (MAFLD) cites a prevalence of about 47.5%, with 56.7% of those studied having fibrosis, against a global prevalence of about 25%. A recent editorial gives 45% (about 25.7 million people) for MASLD and cautions that such figures need to be read critically.
  • In Egypt, diagnosis relies mostly on ultrasound and non-invasive fibrosis scores such as FIB-4, because elastography is concentrated in specialist centres.
  • A survey of 584 physicians in Saudi Arabia, Egypt and Turkey found a knowledge deficit in identifying and managing MASLD, most marked in primary care, and fatty liver is often found by chance on imaging or tests ordered for other reasons.
  • A clinic can follow these patients with a registry, a metabolic check, a FIB-4 risk band set by the doctor, a referral path and a recall date. The clinic organises the routine; the doctor decides the management.
Illustrative fatty liver risk check and clinic follow-up calendar
On this page

Why fatty liver findings get lost

Many patients first hear about fatty liver from an ultrasound report that says the liver is bright and suggests lab correlation. They leave with the report and often no plan. The regional review of MASLD in challenging care settings describes exactly this: it is frequently diagnosed incidentally, primary care providers are not always prepared to stage it, and referral pathways are fragmented. Patients type the same questions into search engines: does it need follow-up, which doctor should I see, can it be reversed.

The scale makes this a clinic issue. The Egyptian practice guidance cites studies placing MAFLD prevalence at about 47.5% and the editorial on MASLD prevention cites 45%. Whatever the exact number, a private clinic that does ultrasound, internal medicine or diabetes care will see many patients with this finding.

What the Egyptian guidance proposes

The Egyptian MAFLD practice guidance describes a primary-care-based multidisciplinary model: initial identification in primary care, with an attached referral pathway to specialist care. The editorial from Egypt describes standardised use of FIB-4 and the NAFLD fibrosis score for risk stratification in primary care as a way to prioritise limited advanced resources for the patients who need them most. These are models, not clinic rules. The doctor and the hepatologist decide what to apply.

What the program contains

  1. A registry of patients with the finding. Anyone whose ultrasound or record shows fatty liver is listed with the date, the referring doctor and the responsible clinician.
  2. A metabolic check. Diabetes, blood pressure, lipids and weight are recorded in the same place, because they are the main risk factors reported for MASLD in Egyptian studies. If the patient has diabetes, hypertension or obesity, the clinic can reuse the program it already runs.
  3. A fibrosis risk score. FIB-4 uses age, AST, ALT and platelet count, so the clinic can calculate it from a routine blood test. A primary-care cohort in the United States used these four values to stratify patients into low, indeterminate and high likelihood of advanced fibrosis. The doctor sets the thresholds and the actions.
  4. A referral rule. The doctor decides which risk band goes to a hepatologist, and the clinic tracks that the appointment happened. Our guide to hepatitis C post-treatment follow-up shows the same pattern for a liver specialty referral.
  5. Lifestyle follow-up. Short, repeated guidance in Arabic on diet and activity, with a named person who asks about it at each contact. The content comes from the doctor or dietitian.
  6. A recall date by risk band. Each patient has a next-check date set by the doctor, and a missed date triggers a call.
  7. A hand-back. Results and the plan go back to the referring doctor in one page.

Where patients are lost

The ultrasound report is filed. The blood test is done once. The patient feels well and does not return. A high-risk result sits in the chart. The patient is told to see a hepatologist and never goes. These are small, ordinary gaps, and each one is visible only if someone has a list.

What a digital tool adds, and what it does not

A tool can hold the registry, store the FIB-4 inputs and the date, show the risk band the doctor set, list patients with no recall date, send reminders by WhatsApp or SMS to patients who agreed to them, and show whether a referral was completed. It does not interpret an ultrasound, stage fibrosis or decide treatment.

Data protection

Liver and metabolic records are health data. Reminders should go only to patients who agreed to receive them, and family members should be added only with the patient's agreement. Egypt's Personal Data Protection Law (Law No. 151 of 2020) applies to personal data processing, so confirm consent, access and storage rules with your own legal adviser. See our guide to patient data privacy under Law 151.

An illustrative scenario

This is a hypothetical example, not a real patient. A 44-year-old man with type 2 diabetes has an ultrasound at a clinic in Nasr City that reports a bright liver. The receptionist adds him to the fatty liver registry. The nurse records his weight and blood pressure, and the lab sends age, AST, ALT and platelet count so the system can show his FIB-4 risk band. The doctor reviews the band, writes a referral rule and sets a recall date. Three weeks later the list shows that the referral has not been completed; the nurse calls him and rebooks. Nothing about the doctor's judgement changed. What changed is that the finding became a follow-up.

Start small

Pull the last three months of ultrasound reports that mention fatty liver. Count how many patients have a recorded FIB-4 or a plan. That count is your baseline.

Frequently asked questions

Does fatty liver need follow-up?

Doctors usually want to know whether a fatty liver finding comes with fibrosis risk and metabolic conditions. A clinic follow-up program makes sure that question is asked, answered and recorded. The doctor decides what follow-up each patient needs.

Which doctor should a patient with fatty liver see?

Often the first doctor is the family physician, internist or diabetologist, with a referral to a hepatologist when the doctor judges the risk to be higher. The clinic should write down who the patient sees next.

What is FIB-4?

FIB-4 is a non-invasive score calculated from age, AST, ALT and platelet count, used to estimate the likelihood of advanced liver fibrosis. The doctor interprets it.

How often should fatty liver be re-checked?

The interval is set by the doctor according to risk. A recall date for every patient, and a call when it is missed, keeps the plan from depending on the patient's memory.

Can the clinic send reminders for follow-up?

Yes, if the patient agreed to receive them and the clinic follows its consent and data protection rules. Reminders work best when a named person acts on the overdue list.

Sources

Book a CareSync demo